ArticleJournal of clinical orthopaedics and trauma2025
Use of Ceftaroline for prosthetic joint infections and spinal hardware infections.
Article in Journal of clinical orthopaedics and trauma, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Ceftaroline is an alternative antibiotic for the treatment of prosthetic joint infections (PJI) and spinal hardware infections (SHI) given its broad spectrum of activity. Yet there is a paucity of data on the use of ceftaroline in the treatment of these infections. Consequently, the aim of this study was to conduct a retrospective cohort study evaluating the use of ceftaroline to treat PJI and SHI. Methods: Identification of patients was conducted through a query of the hospital's antibiotic stewardship database for inpatient use of ceftaroline from 1/1/2020-1/1/2024. Patients were included if ceftaroline was used to treat PJI or SHI for longer than 14 days. The primary outcomes were adverse drug reactions to ceftaroline use and recurrence of infection. Results: There were 16 PJI and 19 SHI who were treated with long term ceftaroline. The rate of adverse drug reactions was 15.8 % in the SHI cohort and 12.5 % in the PJI cohort and recurrence rates were 15.8 % and 12.5 % in the SHI and PJI cohort respectively. Moreover, successful outcomes occurred in 80 % of patients with daptomycin and/or vancomycin intermediate/resistant Discussion: Ceftaroline is a viable alternative antibiotic in the treatment of complex Gram-positive, such as methicillin resistant
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.